GentleLASE Family of Laser Systems 510k Summary MAR 3 1 2003
General Information: a (
This 510(k) is to provide notification of substantial equivalence for the Candela GentleLASE Family of
Laser Systems, which is substantially equivalent to previously marketed devices . The GentleLASE Family
of lasers is indicated for use for the treatment of benign pigmented lesions.
Submitted by: Candela Corporation
530 Boston Post Road
Wayland, MA 01778-1886
Contact Person: William H. McGrail
Date prepared: December 30, 2002
Classification: Class II (21 CFR § 878.4810 Laser Surgical Instrument for use in
General and Plastic Surgery and in Dermatology)
Common Name: Dermatology Laser, GentleLASE Family of Laser Systems
Predicate Devices: Candela Gentle_LASE GL (K994260)
Description:
The Candela GentleLASE Family of Lasers utilizes an Alexandrite rod (crystal) which emits pulsed
energy at 755 nanometers in the near infrared region. Energy from the laser is directed to the target area
via optical fiber/handpiece delivery system. The laser output energy is delivered via an optical fiber to a
handpiece, which produces a circular beam on the skin. The GentleLASE Family of Laser Systems are
designed with six major components:
1. High voltage power supply and modulator system
2. Optical laser head
3. Circulator system
4. Optical delivery system
5. Software control system
The Candela GentleLASE Family of Laser Systems are equipped with safety interlock systems to protect
patients and operators. Users of the device make selections from an onboard control panel to regulate
operation during treatment.

GentleLASE Family of Laser Systems 510k Summary
Testing:
As laser products, the GentleLASE Family of laser Systems are required to conform and does conform to
the Laser Performance Standard (21 CFR 1040). In addition the GentleLASE Family of Laser Systems
conforms to the UL 2601 Electrical Safety Standard and with the Harmonized Standard EN 60601-1-2.
Part 2 established by and required by the European Community.
Safety and Effectiveness Information:
The indications for use for the treatment of benign pigmented lesions is based on a controlled clinical
study using a device that has been cleared for use in the market. We therefore believe that there are no
questions of safety or effectiveness raised by the introduction of the Candela GentleLASE Family of Laser
Systems.
Summary of Substantial Equivalence:
The Candela GentleLASE Family of Laser Systems have the same intended use, utilizes similar operating
principles, design aspects, spot size, wavelength, and fluence as the predicate devices.
On the basis of similarities in methods of assembly, method of operation, and intended uses. Candela
Corporation believes that the Candela GentleLASE Family of Laser Systems is substantially equivalent to
the predicate devices.

nny,
f DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
LG
nes Food and Drug Administration
9200 Corporate Boulevard
MAR 31 2003 Rockville MD 20850
Mr. William H. McGrail
Vice President of Research & Development
and Operations
Candela Corporation
530 Boston Post Road
Wayland, Massachusetts 01778-1886
Re: K024371
Trade/Device Name: Candela GentleLASE Family of Laser Systems
Regulation Number: 21 CFR 878.4810
Regulation Name: Laser surgical instrument for use in general and
plastic surgery and in dermatology
Regulatory Class: II
Product Code: GEX
Dated: December 30, 2002
Received: December 31, 2002
Dear Mr. McGrail:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications .
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
, commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). ‘
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of :
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 - Mr. William H. McGrail
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the
promotion and advertising of your device, please contact the Office of Compliance at (301) 5944639. Also, please note the regulation entitled, "Misbranding by reference to premarket
notification” (21CFR Part 807.97) you may obtain. Other general information on your
responsibilities under the Act may be obtained from the Division of Smal! Manufacturers,
International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597
or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely yours,
. a a
an C- Purveate
{Celia M. Witten, Ph.D., M.D.
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health
Enclosure

INDICATION FOR USE STATEMENT
510(k) Number (if known): IK ¢ YQ + > | |
Device Names Candela GentleLASE Family of Laser Systems
Indications For Use:
1. Treatment of benign pigmented lesions
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use. OR Over-The-Counter Use
(Per 21 CFR 801.109)
wan ) C Vhevoat
(Division Sign-Off) —
Division of General, Restorative
- and Neurological Devices
y
510(k) Number A22%3 7/ G243
CANDELA CORPORATION 68
530 Boston Post Road, Wayland, Massachusetts 01778 Tel: 508-358-7637 Fax: 508-358-5602

